Reportedly, prior to joining Illumina, Dr Cimler served as president of PandiaDx Consulting, where she provided regulatory and compliance guidance for the development of in vitro diagnostics products and medical devices.

Previously, Dr Cimler had held leadership positions in quality, regulatory and government affairs at Beckman Coulter. She also served in senior quality and regulatory roles at Abbott Molecular and Gen-Probe.

Illumina has granted an option to purchase 120,000 shares of common stock to Dr Cimler as part of her inducement to join the company. The options were granted by Illumina’s Compensation Committee pursuant to Nasdaq Marketplace Rule 5635(c)(4) and under Illumina’s New Hire Stock and Incentive Plan, which was approved by Illumina’s board of directors on January 29, 2008.

Mr Henry said: “We are delighted to welcome Dr Cimler to IlluminaShe brings an impressive breadth of leadership experience in the quality and regulatory areas. I expect she will play a key role as we continue to scale our life sciences business and expand into diagnostics.”